Coordinated IL-2 and TGF-β Signaling via a Novel Fusion Protein Selectively Expands and Activates Regulatory T Cells

The study introduces CUE-401, a novel bifunctional fusion protein that coordinates IL-2 and TGF-β signaling to selectively expand and activate regulatory T cells, thereby inducing immune tolerance and providing long-term protection against autoimmune diseases without broadly activating conventional T cells.

The Gist

Imagine your body's immune system is a highly trained security force. Its job is to spot and destroy invaders like viruses and bacteria. However, sometimes this security force gets confused and starts attacking your own body's healthy tissues. This is what happens in autoimmune diseases (like rheumatoid arthritis, lupus, or type 1 diabetes).

Usually, the immune system has a "peacekeeping squad" called Regulatory T cells (Tregs). Think of these Tregs as the diplomats or traffic cops of the immune system. Their job is to tell the aggressive security guards (effector T cells) to stand down and stop attacking your own body.

In many autoimmune diseases, the problem isn't that the diplomats don't exist; it's that they are too weak, too few in number, or they can't get the right instructions to do their job.

The Problem with Current Treatments

Scientists have tried to boost these peacekeepers using Interleukin-2 (IL-2), a chemical signal that acts like a "growth hormone" for Tregs.

However, there's a catch: IL-2 is like a loudspeaker. When you shout "Grow!" to the peacekeepers, the aggressive security guards hear it too and start growing and attacking even harder. It's hard to give the signal only to the peacekeepers without accidentally waking up the troublemakers.

The New Solution: CUE-401

This paper introduces a new drug called CUE-401. You can think of CUE-401 as a smart, double-sided instruction manual or a specialized delivery drone.

Here is how it works, using a simple analogy:

1. The Two Signals: To turn a regular soldier into a peacekeeper (a Treg), the cell needs two specific signals at the exact same time:

   • Signal A (IL-2): "Grow and multiply."
   • Signal B (TGF-β): "Calm down and become a diplomat."
   • The Challenge: In the body, these signals usually arrive separately or get lost. If you send them separately, the aggressive guards might get Signal A and attack, while the peacekeepers miss Signal B and stay weak.

2. The "Velcro" Trick: CUE-401 is a single molecule that physically ties Signal A and Signal B together.

   • It has a weakened IL-2 part (so it doesn't scream too loudly at the wrong cells).
   • It has a masked TGF-β part (it's covered up so it doesn't activate until it finds the right target).
   • They are glued together on a backbone (an Fc scaffold) that keeps them stable in the bloodstream.

3. The "Key and Lock" Mechanism:

   • Imagine the peacekeepers (Tregs) have a special lock that requires two keys to open at the exact same moment.
   • The aggressive guards (regular T cells) only have a lock for one key.
   • Because CUE-401 holds both keys together, it can only unlock the peacekeepers. The aggressive guards can't open the door because they are missing the second key (the masked TGF-β) or because the "growth" part of the drug is too weak to trigger them on its own.

What Happened in the Experiments?

The researchers tested this "smart drone" in mice with autoimmune diseases (specifically, a condition where the stomach gets attacked).

• In the Lab: When they mixed CUE-401 with immune cells, it successfully turned regular cells into peacekeepers and made existing peacekeepers stronger and more numerous. Crucially, it stopped the aggressive cells from making inflammatory chemicals.
• In the Mice:
  • The Boost: A single dose of CUE-401 caused the population of peacekeepers (Tregs) to explode in number.
  • The Quality: These new peacekeepers weren't just numerous; they were "high-quality." They were stable, meaning they wouldn't easily turn back into aggressive soldiers later. They were also "activated," meaning they were ready to work immediately.
  • The Selectivity: Unlike older drugs that woke up the aggressive guards, CUE-401 left the aggressive guards mostly alone. It was a "surgical strike" for peace.
  • The Result: The mice that received CUE-401 were protected from autoimmune gastritis (stomach inflammation). Even though the treatment was short (just one or two doses), the protection lasted for a long time. The peacekeepers they created stayed in the body and kept the peace.

The Big Picture

Think of CUE-401 as a precision tool that teaches the immune system how to be calm again. Instead of using a sledgehammer (broad immunosuppression) that knocks out the whole immune system, or a loudspeaker (standard IL-2) that accidentally fuels the fire, CUE-401 is a targeted whisper that only the peacekeepers can hear.

This suggests a new way to treat autoimmune diseases: instead of just suppressing the immune system, we can retrain it to tolerate the body's own tissues, potentially offering a long-term cure with just a few doses of medicine.

Technical Summary

1. Problem Statement

Autoimmune diseases result from a breakdown in peripheral immune tolerance. Regulatory T cells (Tregs) are critical for maintaining this tolerance, but their therapeutic application is limited by the difficulty of selectively expanding and activating them in vivo without simultaneously activating pathogenic effector T cells (Tconvs).

• Current Limitations: While IL-2 is known to expand Tregs, it also activates Tconvs (which express the intermediate-affinity IL-2 receptor), leading to a narrow therapeutic window. Furthermore, TGF-β is essential for Treg induction and stability, but its short half-life and the challenge of co-delivering both cytokines to the same target cell have hindered effective combination therapies.
• Goal: Develop a bifunctional biologic that coordinates IL-2 and TGF-β signaling specifically on Tregs to induce, expand, and stabilize them while minimizing off-target activation of effector T cells.

2. Methodology

The authors designed and characterized CUE-401, a novel fusion protein, and evaluated its efficacy through in vitro assays and multiple in vivo mouse models.

• Molecule Design (CUE-401):
  • Structure: A heterodimeric Fc-based fusion protein.
  • IL-2 Component: An attenuated IL-2 mutein (F42A, H16A mutations) with reduced affinity for CD25 (IL-2Rα) and CD122 (IL-2Rβ) to limit Tconv activation.
  • TGF-β Component: A receptor-masked, attenuated TGF-β3 variant. It includes a C77S mutation to prevent disulfide bonding and a "mask" (modified TGFβR2 extracellular domain) that prevents premature receptor binding until the molecule engages the cell surface.
  • Linker/Scaffold: Flexible linkers connect the cytokines to an Fc scaffold to extend serum half-life and promote co-signaling.
• In Vitro Assays:
  • CTLL-2 Proliferation: To quantify IL-2 activity.
  • SMAD2/3 Phosphorylation: To confirm TGF-β pathway activation.
  • Treg Induction/Expansion: Sorted naïve CD4+ T cells and endogenous Tregs were stimulated with CUE-401, rhIL-2, or rhIL-2 + rhTGF-β3. Foxp3 expression and cytokine secretion (IFN-γ, IL-4, TNF, IL-17A) were measured.
• In Vivo Models:
  • Pharmacodynamics: BALB/c mice received a single dose of CUE-401. Treg frequency, phenotype (GITR, CD25, CTLA-4, CD103), and stability (TSDR demethylation of the Foxp3 locus) were analyzed via flow cytometry and bulk RNA-seq.
  • Comparative Study: CUE-401 was compared to a control lacking TGF-β (CUE-401ΔTGF-β3) to isolate the contribution of TGF-β signaling.
  • Autoimmune Gastritis Model: A Treg-deficiency-driven model where CD25-depleted splenocytes and autoreactive TCR-transgenic T cells (specific for H+/K+ ATPase) were transferred into athymic nu/nu mice. Mice were treated with CUE-401 or PBS on days 1 and 14. Outcomes included gastric infiltration of autoreactive T cells and histopathological scoring.
• Omics Analysis: Bulk RNA-seq and Single-cell RNA-seq (scRNA-seq) were performed on sorted Tregs and Tconvs to define transcriptional programs and signaling signatures (e.g., IL-2/STAT5).

3. Key Contributions

• Novel Mechanism of Action: Demonstrated that physically linking attenuated IL-2 and receptor-masked TGF-β3 creates a "co-signaling" unit that preferentially targets Tregs.
• Selectivity: Showed that CUE-401 expands Tregs without the broad activation of conventional T cells (Tconvs) typically seen with IL-2 monotherapy.
• Stability: Proved that CUE-401 induces Tregs with stable epigenetic signatures (TSDR demethylation) and long-term suppressive capacity.
• Therapeutic Efficacy: Established that early, transient administration of CUE-401 provides durable protection against autoimmune gastritis in a severe Treg-deficiency model.

4. Key Results

A. Biological Activity and Specificity

• Signaling: CUE-401 successfully triggered both IL-2 (CTLL-2 proliferation) and TGF-β (SMAD2/3 phosphorylation) pathways.
• Treg Induction: In vitro, CUE-401 induced >75% of naïve CD4+ T cells to convert into Foxp3+ induced Tregs (iTregs), comparable to the combination of rhIL-2 + rhTGF-β3, but superior to IL-2 alone (~1%).
• Effector Suppression: CUE-401 significantly reduced the secretion of pro-inflammatory cytokines (IFN-γ, IL-4, TNF) from effector/memory T cells compared to IL-2 treatment.
• Selectivity vs. IL-2 Alone: While CUE-401ΔTGF-β3 (IL-2 only) expanded Tregs, it also activated Tconvs (increasing CD25/CD103 and effector genes like Gzmb, Eomes). CUE-401 (with TGF-β) expanded Tregs without activating Tconvs, effectively constraining the off-target response.

B. In Vivo Expansion and Phenotype

• Expansion: A single dose of CUE-401 increased splenic Treg frequency from ~20% (control) to ~61% of CD4+ T cells by day 6.
• Stability: Tregs expanded by CUE-401 exhibited complete demethylation of the Foxp3 TSDR (CNS2), a marker of lineage commitment, and maintained Foxp3 expression after 6 days of restimulation without cytokines.
• Activation: Expanded Tregs showed an activated phenotype with high expression of GITR, CD25, CTLA-4, and CD103.
• Transcriptomics: Bulk RNA-seq revealed that CUE-401 induced a unique transcriptional program in Tregs, distinct from IL-2 alone. It upregulated Treg-specific genes (Ctla4, Lag3, Il2ra) and TGF-β-regulated genes (Alpk1, Lgmn) while failing to induce the effector-like program seen in Tconvs treated with IL-2 alone.

C. Therapeutic Efficacy in Autoimmunity

• Gastritis Model: In the Treg-deficiency model, CUE-401 treatment significantly reduced the infiltration of autoreactive Thy1.1+ T cells into the gastric mucosa (10% vs. 44% in controls).
• Histopathology: CUE-401 treated mice showed a significant reduction in disease severity (median score 3/12 vs. 6/12 in controls), with reduced inflammation, glandular atrophy, and hyperplasia.
• Long-term Protection: The protection persisted for over 60 days without further treatment, suggesting the induction of a stable, self-sustaining Treg population.
• Mechanism in Disease: scRNA-seq of gastric lymph nodes confirmed that CUE-401 expanded Tregs with a distinct transcriptional signature enriched for IL-2/STAT5 signaling and survival genes (Bcl2l1, Il2ra), distinct from the control group.

5. Significance

This study presents CUE-401 as a promising therapeutic candidate for autoimmune and inflammatory diseases.

• Overcoming Therapeutic Windows: By coordinating IL-2 and TGF-β signals on a single molecule, CUE-401 overcomes the historical trade-off where IL-2 therapies activate pathogenic T cells.
• Epigenetic Stability: Unlike some transient Treg inducers, CUE-401 promotes Tregs with stable epigenetic marks, suggesting long-term tolerance induction rather than temporary suppression.
• Clinical Translation: The molecule is fully human-derived and cross-reactive with mouse receptors, facilitating preclinical-to-clinical translation. The ability to achieve durable remission with early, transient dosing offers a significant advantage over chronic immunosuppression.
• Mechanistic Insight: The work provides a proof-of-concept that physically linked cytokine co-delivery can rewire cellular signaling to bias immune responses toward a regulatory state, a strategy that could be applied to other cytokine pairs.

In conclusion, CUE-401 represents a paradigm shift in Treg-targeted immunotherapy, offering a potent, selective, and durable method to restore immune tolerance in autoimmune settings.